Search
amrinone (Inocor, inamrinone)
Tradename: Inocor. (amrinone lactate)
Indications:
1) short term treatment of refractory acute heart failure
2) may improve hemodynamics in patients receiving:
a) dopamine
b) dobutamine
c) digoxin
Dosage:
1) 0.75 mg/kg bolus IV over 2-3 min, then
2) infusion 100 mg in 100 mL normal saline (1 mg/mL) @ 5-10 ug/kg/min, 70 kg: 21 mL/hr = 5 ug/kg/min
3) max: 10 mg/kg/24 hours
Injection: 5 mg/mL. 20 mL.
Monitor:
1) hemodynamic monitoring
2) CBC
3) electrolytes, especially K+
4) renal & liver function
Pharmacokinetics:
1) IV: onset of action is within 2-5 minutes
2) peak effect occurs within 10 minutes
3) duration of action is dose-dependent
a) 30 minutes with low doses
b) up to 2 hours with higher doses
Adverse effects:
1) not common
a) hypotension
- in patients with:
- receiving vasodilators
- with volume contraction
- may be infuson-related
b) atrial & ventricular arrhythmia
c) thrombocytopenia (may be dose-related)
d) nausea
2) uncommon (< 1%)
- chest pain, fever, vomiting, abdominal pain, anorexia, pain or burning at the site of injection, hepatotoxicity
Mechanism of action:
- hemodynamic effects)
1) similar to dobutamine, but more vasodilatory properties
2) comparable to milrinone
Interactions
drug interactions
drug adverse effects of antihypertensive agents
General
amine
enzyme inhibitor
inotropic agent
vasodilator agent
Properties
INHIBITS: phosphodiesterase
MISC-INFO: elimination route KIDNEY
pregnancy-category C
safety in lactation ?
Database Correlations
PUBCHEM correlations
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Manual of Medical Therapeutics, 28th ed, Ewald &
McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 124
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Deprecated Reference